Literature DB >> 31522868

Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development.

Kristy R Howell1, Amanda J Law2.   

Abstract

Normative brain development is contingent on the complex interplay between genes and environment. Schizophrenia (SCZ) is considered a highly polygenic, neurodevelopmental disorder associated with impaired neural circuit development, neurocognitive function and variations in neurotransmitter signaling systems, including dopamine. Significant evidence, accumulated over the last 30 years indicates a role for the in utero environment in SCZ pathophysiology. Emerging data suggests that changes in placental programming and function may mediate the link between genetic risk, early life complications (ELC) and adverse neurodevelopmental outcomes, with risk highlighted in key developmental drivers that converge on AKT/mTOR signaling. In this article we overview select risk genes identified through recent genome-wide association studies of SCZ including AKT3, miR-137, DRD2, and AKT1 itself. We propose that through convergence on AKT/mTOR signaling, these genes are critical factors directing both placentation and neurodevelopment, influencing risk for SCZ through dysregulation of placental function, metabolism and early brain development. We discuss association of risk genes in the context of their known roles in neurodevelopment, placental expression and their possible mechanistic links to SCZ in the broad context of the 'developmental origins of adult disease' construct. Understanding how common genetic variation impacts early fetal programming may advance our knowledge of disease etiology and identify early critical developmental windows for prevention and intervention.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Developmental origins of disease; GWAS; Placenta; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 31522868      PMCID: PMC7065975          DOI: 10.1016/j.schres.2019.08.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  181 in total

Review 1.  The dopamine hypothesis of schizophrenia: a review.

Authors:  H Y Meltzer; S M Stahl
Journal:  Schizophr Bull       Date:  1976       Impact factor: 9.306

2.  Identification of AKT1 3'UTR variants in two Indian schizophrenia patients with poor executive functioning.

Authors:  Tze Jen Chow; Shiau Foon Tee; Siew Yim Loh; Hoi Sen Yong; Abdul Kadir Abu Bakar; Sze Looi Song; Pek Yee Tang
Journal:  Asian J Psychiatr       Date:  2018-05-22

3.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

4.  Neuregulin 1-induced AKT phosphorylation in monozygotic twins discordant for schizophrenia.

Authors:  Imola Seres; Oguz Kelemen; György Benedek; Szabolcs Kéri
Journal:  Neurochem Int       Date:  2010-04-03       Impact factor: 3.921

Review 5.  Mechanistic Target of Rapamycin Is a Novel Molecular Mechanism Linking Folate Availability and Cell Function.

Authors:  Elena Silva; Fredrick J Rosario; Theresa L Powell; Thomas Jansson
Journal:  J Nutr       Date:  2017-06-07       Impact factor: 4.798

6.  Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.

Authors:  Jian-Ping Zhang; Delbert G Robinson; Juan A Gallego; Majnu John; Jin Yu; Jean Addington; Mauricio Tohen; John M Kane; Anil K Malhotra; Todd Lencz
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

7.  Labelling of D2-dopaminergic and 5-HT2-serotonergic binding sites in human trophoblastic cells using [3H]-spiperone.

Authors:  C Vaillancourt; A Petit; N Gallo-Payet; D Bellabarba; J G Lehoux; S Bélisle
Journal:  J Recept Res       Date:  1994-01

8.  Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.

Authors:  Effat S Emamian; Diana Hall; Morris J Birnbaum; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Genet       Date:  2004-01-25       Impact factor: 38.330

9.  AKT/GSK3 signaling pathway and schizophrenia.

Authors:  Effat S Emamian
Journal:  Front Mol Neurosci       Date:  2012-03-15       Impact factor: 5.639

10.  MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls.

Authors:  D Cosgrove; D Harold; O Mothersill; R Anney; M J Hill; N J Bray; G Blokland; T Petryshen; A Richards; K Mantripragada; M Owen; M C O'Donovan; M Gill; A Corvin; D W Morris; G Donohoe
Journal:  Transl Psychiatry       Date:  2017-01-24       Impact factor: 6.222

View more
  7 in total

1.  GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.

Authors:  Petros Petrikis; Alexandra Polyzou; Kyriaki Premeti; Argyro Roumelioti; Andreas Karampas; Georgios Georgiou; Dionysios Grigoriadis; George Leondaritis
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

2.  Exposure to the Amino Acids Histidine, Lysine, and Threonine Reduces mTOR Activity and Affects Neurodevelopment in a Human Cerebral Organoid Model.

Authors:  Amber Berdenis van Berlekom; Raphael Kübler; Jeske W Hoogeboom; Daniëlle Vonk; Jacqueline A Sluijs; R Jeroen Pasterkamp; Jinte Middeldorp; Aletta D Kraneveld; Johan Garssen; René S Kahn; Elly M Hol; Lot D de Witte; Marco P Boks
Journal:  Nutrients       Date:  2022-05-23       Impact factor: 6.706

3.  Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients.

Authors:  Laura Stertz; Jessica Di Re; Guangsheng Pei; Gabriel R Fries; Emily Mendez; Shenglan Li; Laura Smith-Callahan; Henriette Raventos; Jerricho Tipo; Rohan Cherukuru; Zhongming Zhao; Ying Liu; Peilin Jia; Fernanda Laezza; Consuelo Walss-Bass
Journal:  Neuropsychopharmacology       Date:  2020-12-07       Impact factor: 7.853

4.  Mechanistic Target of Rapamycin Complex 2 Regulation of the Primary Human Trophoblast Cell Transcriptome.

Authors:  Fredrick J Rosario; Amy Catherine Kelly; Madhulika B Gupta; Theresa L Powell; Laura Cox; Thomas Jansson
Journal:  Front Cell Dev Biol       Date:  2021-11-04

5.  Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs.

Authors:  Trang T T Truong; Chiara C Bortolasci; Srisaiyini Kidnapillai; Briana Spolding; Bruna Panizzutti; Zoe S J Liu; Jee Hyun Kim; Olivia M Dean; Mark F Richardson; Michael Berk; Ken Walder
Journal:  Int J Mol Sci       Date:  2022-07-06       Impact factor: 6.208

Review 6.  Insights into Potential Targets for Therapeutic Intervention in Epilepsy.

Authors:  Cecilia Zavala-Tecuapetla; Manola Cuellar-Herrera; Hiram Luna-Munguia
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

7.  Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia.

Authors:  Kana Yamamoto; Toshihiko Kuriu; Kensuke Matsumura; Kazuki Nagayasu; Yoshinori Tsurusaki; Noriko Miyake; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Mikiya Fujiwara; Masayuki Baba; Kohei Kitagawa; Tomoya Takemoto; Nanaka Gotoda-Nishimura; Tomohiro Takada; Kaoru Seiriki; Atsuko Hayata-Takano; Atsushi Kasai; Yukio Ago; Satoshi Kida; Kazuhiro Takuma; Fumihito Ono; Naomichi Matsumoto; Ryota Hashimoto; Hitoshi Hashimoto; Takanobu Nakazawa
Journal:  Transl Psychiatry       Date:  2021-10-25       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.